ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drugs for Spinal Muscular Atrophy (SMA) Market Research Report 2024
Published Date: October 2024
|
Report Code: QYRE-Auto-5B18414
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Drugs for Spinal Muscular Atrophy SMA Market Research Report 2024
BUY CHAPTERS

Global Drugs for Spinal Muscular Atrophy (SMA) Market Research Report 2024

Code: QYRE-Auto-5B18414
Report
October 2024
Pages:76
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Genentech Inc
Biogen
Ionis Pharmaceuticals

Drugs for Spinal Muscular Atrophy (SMA) Market

Drugs for Spinal Muscular Atrophy (SMA) are treatments that address the genetic cause of the disease by increasing levels of the SMN (survival motor neuron) protein. Key therapies include Spinraza (nusinersen), administered via spinal injection, Zolgensma, a one-time gene therapy given through intravenous infusion, and Evrysdi (risdiplam), an oral solution taken daily.
The global Drugs for Spinal Muscular Atrophy (SMA) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Drugs for Spinal Muscular Atrophy (SMA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Drugs for Spinal Muscular Atrophy (SMA) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Drugs for Spinal Muscular Atrophy (SMA) include Novartis, Genentech, Biogen, Ionis Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs for Spinal Muscular Atrophy (SMA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Spinal Muscular Atrophy (SMA).
The Drugs for Spinal Muscular Atrophy (SMA) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Drugs for Spinal Muscular Atrophy (SMA) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Spinal Muscular Atrophy (SMA) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Drugs for Spinal Muscular Atrophy (SMA) Market Report

Report Metric Details
Report Name Drugs for Spinal Muscular Atrophy (SMA) Market
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis, Genentech, Biogen, Ionis Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Drugs for Spinal Muscular Atrophy (SMA) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Drugs for Spinal Muscular Atrophy (SMA) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Drugs for Spinal Muscular Atrophy (SMA) Market report?

Ans: The main players in the Drugs for Spinal Muscular Atrophy (SMA) Market are Novartis, Genentech, Biogen, Ionis Pharmaceuticals

What are the Application segmentation covered in the Drugs for Spinal Muscular Atrophy (SMA) Market report?

Ans: The Applications covered in the Drugs for Spinal Muscular Atrophy (SMA) Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Drugs for Spinal Muscular Atrophy (SMA) Market report?

Ans: The Types covered in the Drugs for Spinal Muscular Atrophy (SMA) Market report are Oral Drugs, Injections

Recommended Reports

Muscular & Nerve Disorders

Myopathy & Dystrophy

Neurology Pharmaceuticals

1 Drugs for Spinal Muscular Atrophy (SMA) Market Overview
1.1 Product Definition
1.2 Drugs for Spinal Muscular Atrophy (SMA) by Type
1.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Value Comparison by Type (2024-2030)
1.2.2 Oral Drugs
1.2.3 Injections
1.3 Drugs for Spinal Muscular Atrophy (SMA) by Application
1.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size Estimates and Forecasts
1.4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue 2019-2030
1.4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales 2019-2030
1.4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Drugs for Spinal Muscular Atrophy (SMA) Market Competition by Manufacturers
2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Drugs for Spinal Muscular Atrophy (SMA), Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Product Type & Application
2.7 Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Date of Enter into This Industry
2.8 Global Drugs for Spinal Muscular Atrophy (SMA) Market Competitive Situation and Trends
2.8.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Drugs for Spinal Muscular Atrophy (SMA) Players Market Share by Revenue
2.8.3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Drugs for Spinal Muscular Atrophy (SMA) Market Scenario by Region
3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2019-2030
3.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2019-2024
3.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region: 2025-2030
3.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2019-2030
3.3.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2019-2024
3.3.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2025-2030
3.4 North America Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.4.1 North America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2019-2030)
3.4.3 North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.5.1 Europe Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2019-2030)
3.5.3 Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Region
3.6.1 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2019-2030)
3.6.3 Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.7.1 Latin America Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2019-2030)
3.7.3 Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2019-2030)
4.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2019-2024)
4.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Type (2025-2030)
4.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2019-2030)
4.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2019-2030)
4.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2019-2024)
4.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Type (2025-2030)
4.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2019-2030)
4.3 Global Drugs for Spinal Muscular Atrophy (SMA) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2019-2030)
5.1.1 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2019-2024)
5.1.2 Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Application (2025-2030)
5.1.3 Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2019-2030)
5.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2019-2030)
5.2.1 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2019-2024)
5.2.2 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Application (2025-2030)
5.2.3 Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2019-2030)
5.3 Global Drugs for Spinal Muscular Atrophy (SMA) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Genentech
6.2.1 Genentech Company Information
6.2.2 Genentech Description and Business Overview
6.2.3 Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Genentech Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.2.5 Genentech Recent Developments/Updates
6.3 Biogen
6.3.1 Biogen Company Information
6.3.2 Biogen Description and Business Overview
6.3.3 Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biogen Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.3.5 Biogen Recent Developments/Updates
6.4 Ionis Pharmaceuticals
6.4.1 Ionis Pharmaceuticals Company Information
6.4.2 Ionis Pharmaceuticals Description and Business Overview
6.4.3 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product Portfolio
6.4.5 Ionis Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Spinal Muscular Atrophy (SMA) Industry Chain Analysis
7.2 Drugs for Spinal Muscular Atrophy (SMA) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Spinal Muscular Atrophy (SMA) Production Mode & Process
7.4 Drugs for Spinal Muscular Atrophy (SMA) Sales and Marketing
7.4.1 Drugs for Spinal Muscular Atrophy (SMA) Sales Channels
7.4.2 Drugs for Spinal Muscular Atrophy (SMA) Distributors
7.5 Drugs for Spinal Muscular Atrophy (SMA) Customers
8 Drugs for Spinal Muscular Atrophy (SMA) Market Dynamics
8.1 Drugs for Spinal Muscular Atrophy (SMA) Industry Trends
8.2 Drugs for Spinal Muscular Atrophy (SMA) Market Drivers
8.3 Drugs for Spinal Muscular Atrophy (SMA) Market Challenges
8.4 Drugs for Spinal Muscular Atrophy (SMA) Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novartis
Genentech Inc
Biogen
Ionis Pharmaceuticals
List of Tables
 Table 1. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Drugs for Spinal Muscular Atrophy (SMA) Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Drugs for Spinal Muscular Atrophy (SMA) Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Drugs for Spinal Muscular Atrophy (SMA), Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Product Type & Application
 Table 12. Global Key Manufacturers of Drugs for Spinal Muscular Atrophy (SMA), Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Drugs for Spinal Muscular Atrophy (SMA) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Spinal Muscular Atrophy (SMA) as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2019-2024) & (K Units)
 Table 18. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2019-2024)
 Table 19. Global Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2025-2030) & (K Units)
 Table 20. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2025-2030)
 Table 21. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2019-2024)
 Table 23. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2025-2030)
 Table 25. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2019-2024) & (K Units)
 Table 27. North America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2025-2030) & (K Units)
 Table 28. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Type (2019-2024)
 Table 51. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Type (2025-2030)
 Table 52. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2019-2024)
 Table 53. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Type (2025-2030)
 Table 54. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2019-2024)
 Table 57. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Type (2025-2030)
 Table 58. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Application (2019-2024)
 Table 61. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units) by Application (2025-2030)
 Table 62. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2019-2024)
 Table 63. Global Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Application (2025-2030)
 Table 64. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2019-2024)
 Table 67. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Application (2025-2030)
 Table 68. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2025-2030)
 Table 70. Novartis Company Information
 Table 71. Novartis Description and Business Overview
 Table 72. Novartis Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Novartis Drugs for Spinal Muscular Atrophy (SMA) Product
 Table 74. Novartis Recent Developments/Updates
 Table 75. Genentech Company Information
 Table 76. Genentech Description and Business Overview
 Table 77. Genentech Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Genentech Drugs for Spinal Muscular Atrophy (SMA) Product
 Table 79. Genentech Recent Developments/Updates
 Table 80. Biogen Company Information
 Table 81. Biogen Description and Business Overview
 Table 82. Biogen Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Biogen Drugs for Spinal Muscular Atrophy (SMA) Product
 Table 84. Biogen Recent Developments/Updates
 Table 85. Ionis Pharmaceuticals Company Information
 Table 86. Ionis Pharmaceuticals Description and Business Overview
 Table 87. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Ionis Pharmaceuticals Drugs for Spinal Muscular Atrophy (SMA) Product
 Table 89. Ionis Pharmaceuticals Recent Developments/Updates
 Table 90. Key Raw Materials Lists
 Table 91. Raw Materials Key Suppliers Lists
 Table 92. Drugs for Spinal Muscular Atrophy (SMA) Distributors List
 Table 93. Drugs for Spinal Muscular Atrophy (SMA) Customers List
 Table 94. Drugs for Spinal Muscular Atrophy (SMA) Market Trends
 Table 95. Drugs for Spinal Muscular Atrophy (SMA) Market Drivers
 Table 96. Drugs for Spinal Muscular Atrophy (SMA) Market Challenges
 Table 97. Drugs for Spinal Muscular Atrophy (SMA) Market Restraints
 Table 98. Research Programs/Design for This Report
 Table 99. Key Data Information from Secondary Sources
 Table 100. Key Data Information from Primary Sources
 Table 101. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Drugs for Spinal Muscular Atrophy (SMA)
 Figure 2. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Type: 2023 & 2030
 Figure 4. Oral Drugs Product Picture
 Figure 5. Injections Product Picture
 Figure 6. Global Drugs for Spinal Muscular Atrophy (SMA) Market Value by Application (2024-2030) & (US$ Million)
 Figure 7. Global Drugs for Spinal Muscular Atrophy (SMA) Market Share by Application: 2023 & 2030
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Other
 Figure 11. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 12. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size (2019-2030) & (US$ Million)
 Figure 13. Global Drugs for Spinal Muscular Atrophy (SMA) Sales (2019-2030) & (K Units)
 Figure 14. Global Drugs for Spinal Muscular Atrophy (SMA) Average Price (US$/Unit) & (2019-2030)
 Figure 15. Drugs for Spinal Muscular Atrophy (SMA) Report Years Considered
 Figure 16. Drugs for Spinal Muscular Atrophy (SMA) Sales Share by Manufacturers in 2023
 Figure 17. Global Drugs for Spinal Muscular Atrophy (SMA) Revenue Share by Manufacturers in 2023
 Figure 18. Global 5 and 10 Largest Drugs for Spinal Muscular Atrophy (SMA) Players: Market Share by Revenue in Drugs for Spinal Muscular Atrophy (SMA) in 2023
 Figure 19. Drugs for Spinal Muscular Atrophy (SMA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 20. Global Drugs for Spinal Muscular Atrophy (SMA) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 21. North America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2019-2030)
 Figure 22. North America Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2019-2030)
 Figure 23. United States Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 24. Canada Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Europe Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2019-2030)
 Figure 26. Europe Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2019-2030)
 Figure 27. Germany Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. France Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. U.K. Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. Italy Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Russia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Region (2019-2030)
 Figure 33. Asia Pacific Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Region (2019-2030)
 Figure 34. China Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Japan Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. South Korea Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. India Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Australia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. China Taiwan Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Southeast Asia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Latin America Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2019-2030)
 Figure 42. Mexico Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Brazil Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Argentina Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Colombia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Sales Market Share by Country (2019-2030)
 Figure 47. Middle East and Africa Drugs for Spinal Muscular Atrophy (SMA) Revenue Market Share by Country (2019-2030)
 Figure 48. Turkey Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Saudi Arabia Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. UAE Drugs for Spinal Muscular Atrophy (SMA) Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Global Sales Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Type (2019-2030)
 Figure 52. Global Revenue Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Type (2019-2030)
 Figure 53. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Type (2019-2030)
 Figure 54. Global Sales Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Application (2019-2030)
 Figure 55. Global Revenue Market Share of Drugs for Spinal Muscular Atrophy (SMA) by Application (2019-2030)
 Figure 56. Global Drugs for Spinal Muscular Atrophy (SMA) Price (US$/Unit) by Application (2019-2030)
 Figure 57. Drugs for Spinal Muscular Atrophy (SMA) Value Chain
 Figure 58. Drugs for Spinal Muscular Atrophy (SMA) Production Process
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Spinal Muscular Atrophy SMA Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Injections for SMA Market Research Report 2024
Global Nusinersen Market Research Report 2024
Global Spinal Muscular Atrophy SMA Treatment Market Research Report 2024
Spinal Muscular Atrophy SMA Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Spinal Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Clinical Trial Capsules Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Spinal Muscular Atrophy Medicine Market Research Report 2025
Spinal and Bulbar Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Bulbospinal Muscular Atrophy Drugs Market Research Report 2024
Global Spinal Muscular Atrophy Genetic Detection Market Research Report 2024
Global Multiple System Atrophy Therapeutics Market Research Report 2024
Global Musculoskeletal System Disorder Drug Market Research Report 2024
Global Geographic Atrophy Drugs Market Research Report 2024
Global Atropine Sulfate for Injection Market Research Report 2024
Myotonic Muscular Dystrophy DMD Treatments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Musculoskeletal System Disorder Therapeutics Market Research Report 2024
Global Baclofe Injection Market Research Report 2024
Global Protein based Drug Market Research Report 2024
Global AAV Vector Based Gene Therapy Drugs Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions